Tenet Healthcare
THC
$206.77
+0.25%
Tenet Healthcare is a Dallas-based healthcare services organization that operates acute and specialty hospitals, ambulatory surgery centers, and outpatient facilities across the southern United States, along with a revenue cycle management segment called Conifer. As one of the largest for-profit hospital operators in the country, it distinguishes itself through an integrated care model spanning hospital and outpatient services. The current investor narrative centers on Tenet's ability to sustain margin expansion and earnings growth amid a challenging payer mix, as evidenced by its recent Q1 2026 earnings beat and raised full-year profit guidance despite softer revenue from unfavorable insurance admissions.…
THC
Tenet Healthcare
$206.77
Investment Opinion: Should I buy THC Today?
Rating: Buy. Tenet Healthcare offers a compelling risk/reward at current levels, with a trailing P/E of 12.73x (29% discount to sector median), strong free cash flow, and consensus analyst Buy ratings. The core thesis is that margin expansion and earnings growth will drive a valuation re-rating.
Supporting Evidence: The forward P/E of 11.50x implies earnings growth, with analysts estimating EPS of $22.74 for the current fiscal year. Revenue grew 8.97% YoY in Q4 2025, and gross margin improved to 41.5% from 40.3%. Free cash flow TTM of $2.53 billion provides a 5.06x P/CF ratio, and ROE of 33.3% reflects efficient capital use. The implied upside to the average analyst target (if available) would be positive given bullish ratings.
Risks & Conditions: The biggest risks are high debt (D/E 3.12x), payer mix headwinds, and potential regulatory changes. This Buy rating would be downgraded to Hold if revenue growth decelerates below 3% or if net margin falls below 5%. Upgrade to Strong Buy if the P/E compresses below 10x or if the company announces significant debt reduction. Overall, Tenet appears undervalued relative to its history and peers, with a clear path to re-rating if earnings momentum continues.
Sign up to view all
THC 12-Month Price Forecast
Tenet Healthcare appears undervalued relative to its earnings power and peer group, with strong free cash flow and improving margins. The primary risk is the high debt load and payer mix headwinds, but the valuation discount provides a margin of safety. The base case of steady growth is most likely, but the bull case has a meaningful probability if the company executes well. We would upgrade our stance if revenue growth accelerates above 6% or if debt-to-equity falls below 2.5x, and downgrade if net margin drops below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tenet Healthcare's 12-month outlook, with a consensus price target around $268.80 and implied upside of +30.0% versus the current price.
Average Target
$268.80
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$165 - $269
Analyst target range
Tenet is covered by 4 analysts, with a consensus leaning bullish. All recent ratings from firms like Guggenheim, Mizuho, and RBC Capital are Buy or Outperform, with no Sell ratings. The average EPS estimate for the current fiscal year is $22.74, with a range of $22.37 to $23.28, implying strong earnings growth. The average revenue estimate is $24.08 billion, with a low of $23.78 billion and high of $24.52 billion. While specific price targets are not provided, the consensus recommendation is Buy. The implied upside from the current price of $203.72 to the average target (if available) would be positive given the bullish sentiment. The high target likely assumes continued margin expansion and successful outpatient growth, while the low target may reflect concerns about payer mix and regulatory risks. The narrow EPS range suggests relatively high conviction among analysts. The lack of explicit price targets is a limitation, but the uniform bullish ratings indicate strong institutional support.
Drowning in data?
Find the real signal!
Bulls vs Bears: THC Investment Factors
Tenet Healthcare presents a mixed picture: strong earnings growth, attractive valuation, and robust free cash flow are countered by high debt, revenue deceleration, and payer mix risks. The bull case is supported by a 29% P/E discount to peers and consistent margin improvement, while the bear case centers on leverage and admissions mix headwinds. The single most important tension is whether Tenet can sustain its margin expansion and earnings growth trajectory despite a challenging payer mix—if it does, the stock could re-rate higher; if not, the high debt load could amplify downside. Currently, the evidence slightly favors the bull case given the valuation discount and analyst optimism, but the risk of a slowdown warrants caution.
Bullish
- Strong Earnings Growth and Margin Expansion: Q4 2025 EPS of $4.25 grew 27.2% YoY from $3.34, driven by net income of $371 million (net margin 6.7%). Gross margin improved to 41.5% from 40.3% a year ago, and operating margin remained robust at 15.4%, demonstrating operational efficiency.
- Attractive Valuation vs. Peers and History: Trailing P/E of 12.73x is a 29% discount to the Medical-Care Facilities sector median of ~18x. The forward P/E of 11.50x implies further earnings growth, and the current P/E is near the lower end of its five-year range (1.2x-37.3x), suggesting limited downside risk.
- Strong Free Cash Flow Generation: Trailing twelve-month free cash flow reached $2.53 billion, providing ample liquidity for debt reduction, share buybacks, or strategic investments. Q4 2025 FCF was $367 million, supporting the company's financial flexibility.
- Consensus Analyst Optimism: All 4 covering analysts rate the stock Buy or Outperform, with an average EPS estimate of $22.74 for the current fiscal year. The narrow EPS range ($22.37-$23.28) indicates high conviction in earnings growth.
Bearish
- High Debt-to-Equity Ratio: Debt-to-equity of 3.12x is elevated, typical for hospital operators but amplifying financial risk. Interest expense of ~$206 million per quarter pressures net income, and any rise in interest rates could further strain earnings.
- Revenue Growth Deceleration and Mix Headwinds: Q1 2026 revenue of $5.227 billion was slightly below the prior quarter, and the company cited an unfavorable admissions mix (more government-insured patients) as a headwind. TTM revenue growth of ~4.6% is modest for a growth stock.
- Recent Price Volatility and Technical Resistance: The stock has pulled back 17.6% from its 52-week high of $247.21, and the 1-month gain of +24.5% contrasts with a flattish 6-month trend, suggesting potential mean reversion. Beta of 1.266 implies higher volatility than the market.
- Payer Mix and Regulatory Risks: Reliance on government payers (Medicare/Medicaid) exposes Tenet to reimbursement cuts or policy changes. The unfavorable insurance mix in Q1 2026 highlights this vulnerability, and any adverse regulatory developments could compress margins.
THC Technical Analysis
Tenet's 1-year price change of +18.3% reflects a sustained uptrend, though the stock has pulled back significantly from its 52-week high of $247.21. As of July 2, 2026, the stock closed at $203.72, which is 82.4% of its 52-week range (between $146.60 low and $247.21 high), indicating it is trading in the upper half but well off the peak, suggesting a consolidation phase after a strong run. The current price sits 17.6% below the high, hinting at potential resistance overhead. Short-term momentum has been robust: the 1-month price change is +24.5%, sharply contrasting with the 3-month change of +8.3% and the 6-month change of +2.1%. This divergence—strong recent gains versus a flattish longer-term trend—suggests a potential short-term reversal or mean reversion, as the stock has rallied from its June low of $161.37. The beta of 1.266 indicates 26.6% more volatility than the S&P 500, amplifying both upside and downside moves. The 52-week low of $146.60 provides a key support level, while the high of $247.21 is a major resistance. A breakout above $247.21 would signal a resumption of the uptrend, while a breakdown below $146.60 could indicate a structural shift. The recent rally from $161.37 to $203.72 suggests buying interest, but the stock remains below its February highs, indicating overhead supply.
Beta
1.27
1.27x market volatility
Max Drawdown
-34.1%
Largest decline past year
52-Week Range
$147-$247
Price range past year
Annual Return
+20.6%
Cumulative gain past year
| Period | THC Return | S&P 500 |
|---|---|---|
| 1m | +24.3% | +2.0% |
| 3m | +5.9% | +10.6% |
| 6m | +2.8% | +8.3% |
| 1y | +20.6% | +20.4% |
| ytd | +3.7% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
THC Fundamental Analysis
Tenet's revenue trajectory shows steady growth, with Q4 2025 revenue of $5.527 billion, up 8.97% year-over-year from $5.072 billion in Q4 2024. However, the most recent quarter (Q1 2026) saw revenue of $5.227 billion, slightly below the prior quarter, and the company cited an unfavorable admissions mix as a headwind. Over the trailing twelve months, revenue has grown from $20.66 billion (FY2024) to an estimated $21.61 billion (FY2025), implying a ~4.6% growth rate. The ambulatory care segment contributed $1.433 billion in the latest quarter, highlighting the shift toward outpatient services. Profitability is solid: net income for Q4 2025 was $371 million, with a net margin of 6.7%. Gross margin improved to 41.5% in Q4 2025 from 40.3% in Q4 2024, while operating margin expanded to 15.4% from 16.2% (slight compression). The company has been consistently profitable, with EPS of $4.25 in Q4 2025 versus $3.34 a year ago, demonstrating earnings growth. The balance sheet shows a debt-to-equity ratio of 3.12, which is high but typical for the hospital industry. Free cash flow for Q4 2025 was $367 million, and trailing twelve-month FCF reached $2.53 billion, providing ample liquidity. The current ratio of 1.76 indicates healthy short-term solvency. ROE of 33.3% is strong, reflecting efficient use of equity, though leverage amplifies this metric.
Quarterly Revenue
$5.5B
2025-12
Revenue YoY Growth
+8.97%
YoY Comparison
Gross Margin
41.52%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is THC Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 12.73x, while the forward P/E is 11.50x, implying the market expects earnings growth. The gap between trailing and forward suggests a modest expansion in earnings expectations. Compared to the industry average (Medical - Care Facilities), Tenet's P/E of 12.73x is at a discount; the sector median P/E is approximately 18x, making Tenet roughly 29% cheaper. This discount may be justified by its higher debt levels and exposure to payer mix risks, but its strong free cash flow and margin improvement support a potential re-rating. Historically, Tenet's trailing P/E has ranged from 1.2x (Q1 2024) to 37.3x (Q2 2022). The current 12.73x is near the lower end of its five-year range, suggesting the stock is not overvalued relative to its own history. The P/S ratio of 0.84x is also below the industry average of ~1.5x, reinforcing a value-oriented profile.
PE
12.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Tenet's debt-to-equity ratio of 3.12x is high, and interest expense of ~$206 million per quarter consumes a significant portion of operating income ($853 million in Q4 2025). While free cash flow of $2.53 billion TTM provides coverage, any sustained earnings decline could pressure debt servicing. Revenue growth is modest at ~4.6% TTM, and the unfavorable admissions mix in Q1 2026 (revenue slightly below prior quarter) highlights operational headwinds. The net margin of 6.7% is solid but sensitive to payer mix shifts.
Market & Competitive Risks: Tenet's beta of 1.266 indicates 26.6% more volatility than the S&P 500, making it susceptible to market downturns. The stock trades at a discount to the sector median P/E of 18x, but this could widen if earnings disappoint. Regulatory risks include potential Medicare/Medicaid reimbursement cuts, which could directly impact revenue. The recent news of soft Q1 sales due to admissions mix underscores competitive pressures from larger hospital systems and ambulatory care centers.
Worst-Case Scenario: A severe recession or adverse regulatory change could cause admissions mix to worsen, compressing margins and triggering analyst downgrades. If earnings fall short of estimates, the stock could retest its 52-week low of $146.60, representing a potential 28% decline from the current price of $203.72. The historical max drawdown of -34.08% suggests a worst-case loss of ~$69 per share, bringing the stock to around $134.
FAQ
The key risks are: (1) Financial risk from high debt (debt-to-equity 3.12x), which amplifies earnings volatility and interest expense (~$206 million per quarter). (2) Payer mix risk, as a shift toward lower-reimbursement government patients (as seen in Q1 2026) can compress margins. (3) Regulatory risk from potential Medicare/Medicaid reimbursement cuts, which could directly reduce revenue. (4) Market risk from the stock's beta of 1.266, making it more volatile than the S&P 500. The most severe risk is a combination of these factors leading to a drop toward the 52-week low of $146.60, a potential 28% decline from current levels.
The 12-month forecast is moderately bullish. The base case (50% probability) sees the stock trading between $190 and $220, driven by steady earnings growth in line with analyst estimates of $22.74 EPS. The bull case (30% probability) targets $220-$247, with catalysts like margin expansion and debt reduction. The bear case (20% probability) sees the stock falling to $147-$170 if payer mix worsens or earnings disappoint. The most likely scenario is the base case, supported by the current valuation discount and analyst consensus. Key assumptions include stable margins and no adverse regulatory changes.
THC appears undervalued based on both peer comparison and its own history. The trailing P/E of 12.73x is well below the Medical-Care Facilities sector median of ~18x, implying a 29% discount. The forward P/E of 11.50x suggests the market expects earnings growth, and the P/S ratio of 0.84x is also below the industry average of ~1.5x. Historically, the stock's P/E has ranged from 1.2x to 37.3x over five years, and the current level is near the lower end, indicating it is not overvalued. The market appears to be pricing in the high debt and payer mix risks, but the strong cash flow and margins suggest the discount may be unwarranted.
Yes, THC appears to be a good buy for value-oriented investors with a medium-term horizon. The stock trades at a trailing P/E of 12.73x, a 29% discount to the sector median of 18x, and analysts are unanimously bullish with a Buy rating. The company has strong free cash flow of $2.53 billion TTM and improving margins (gross margin up to 41.5% from 40.3% YoY). However, the high debt-to-equity of 3.12x and payer mix headwinds introduce risk. For investors comfortable with leverage and healthcare policy exposure, the current valuation offers a favorable risk/reward.
THC is better suited for medium-to-long-term investment (12-24 months) due to its value-oriented profile and the time needed for earnings growth to drive a valuation re-rating. The stock's beta of 1.266 makes it more volatile than the market, which could lead to short-term swings, but the underlying fundamentals (strong FCF, improving margins) support a longer hold. The company does not pay a dividend, so income-focused investors may look elsewhere. A minimum holding period of 12 months is recommended to allow the earnings story to unfold and for the stock to potentially close the valuation gap with peers.
